Response to Case Presentation
Firstly, it is necessary to monitor PT’s reaction to medication due to the aggressive pharmacological intervention. According to Lao, He, Wong, Besag, Chan (2016), cariprazine, which is the primary component of Vraylar has undergone a small number of clinical trials, which implies that PT should be monitored closely throughout his treatment. The author’s assessment provides an understanding of possible extrapyramidal symptoms (EPS), which are typically short-term and present no danger to an individual.
Additionally, Lao et al. (2016) found that body mass may increase while using Vraylar; however, the drug presents no danger for the cardiovascular system. It is necessary to ensure that these drugs provide essential help for dealing with anxiety and bipolar, or change the medication. Because PT complained of having depression and suicidal thoughts in the past, it is also crucial to ensure that this patient can deal with his anxiety through medication and therapy. By assessing his mental state and response to drugs periodically, one would be able to ensure PT’s safety.
The case of PT is interesting because this patient requires aggressive pharmacological treatment because previous attempts to medicate him were ineffective. Thus, it is critical to evaluate the risks and compare them with the outcomes of the decision to adhere to the previous intervention plan. Firstly, PT did not respond to the prescribed dosage of Vraylar displaying irritability and bipolar disorder symptoms. He has a prior history of aggression and suicidal attempts, which present danger for both this patient and others. Moreover, Bobo (2017) states that the condition is life-threatening, displaying an understanding that treatment through various approaches is necessary. Based on this assessment it can be concluded that the decision to increase dosing and add additional medication corresponds with the potential dangers of adhering to the previous treatment plan.
References
Bobo, W. M. (2017). The diagnosis and management of bipolar I and II disorders: Clinical practice update. Mayo Clinic Proceedings, 92(10), 1532-1551. Web.
Lao, K. S., He, Y., Wong, I. C., Besag, F. M., & Chan, E. W. (2016). Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: A systematic review with meta-analysis of randomized controlled trials. CNS Drugs, 30(11), 1043-1054.